ライフサイエンスコーパス: artesunate

1 t to antimalarial treatment with intravenous artesunate.

2 vely, also received >/=1 dose of intravenous artesunate.

3 or with 250 mg of mefloquine plus 100 mg of artesunate.

4 ere observed in those receiving pyronaridine-artesunate.

5 double the chemotherapeutic effect of sodium artesunate.

6 ion with chloroquine (high concentration) or artesunate.

7 nergy with chloroquine (CQ), amodiaquine, or artesunate.

8 f two trioxolanes were comparable to that of artesunate.

9 ective combination of mefloquine and 3 days' artesunate.

10 ong patients treated with prereferral rectal artesunate.

11 r placebo, 25 mg/kg amodiaquine, or 12 mg/kg artesunate.

12 e currently used derivatives, artemether and artesunate.

13 compared with sulfadoxine/pyrimethamine plus artesunate.

14 alone or in combination with 1 or 3 doses of artesunate.

15 dvice for those who were treated with rectal artesunate.

16 ho could not take oral medicines with rectal artesunate.

17 ays after first treatment) with pyronaridine-artesunate.

18 ment of malaria using RDTs, ACTs, and rectal artesunate.

19 42 Malian children treated for malaria with artesunate.

20 n 215 Malian children aged 0.5-15 years with artesunate (0, 24, 48 hours) and amodiaquine (72, 96, 12

21 aridine-artesunate than with mefloquine plus artesunate (10.2% [95% CI, 5.4 to 18.6] vs. 0%; P=0.04 a

22 pyrimethamine (17/129 [13%]) and amodiaquine+artesunate (16/130 [12%]; p=0.854).

23 ally efficacious than clinically used sodium artesunate (2) via both oral and intravenous administrat

24 received 4 weight-based doses of intravenous artesunate (2.4 mg/kg) under a treatment protocol implem

25 Rats were randomly treated with artesunate (2.4 or 4.8 mg/kg i.v.) or vehicle upon resus

26 Rats were randomly treated with artesunate (2.4 or 4.8 mg/kg i.v.) or vehicle upon resus

27 26% [95% CI 16-36]; p<0.0001) or amodiaquine+artesunate (3/130 [2%]; 33% [24-42]; p<0.0001).

28 ulfadoxine-pyrimethamine; or amodiaquine and artesunate (4 mg/kg daily for 3 days).

29 l, -58% [P = .004]; artesunate-primaquine vs artesunate, -49% [P = .031]) with little difference ther

30 d falciparum malaria were randomized to oral artesunate 6 mg/kg/d as a once-daily or twice-daily dose

31 en aged 1-5 years were Randomized to receive artesunate (7 days) plus primaquine (14 days), artesunat

32 temisinin-piperaquine (86.9%), or mefloquine-artesunate (73.8%).

33 (WT) when treated with the antimalarial drug artesunate (77% versus 38%; P < 0.001).

34 nce-daily or twice-daily dose for 7 days, or artesunate 8 mg/kg/d as a once-daily or twice-daily dose

35 5%) than in groups that received amodiaquine-artesunate (82.3%), dihydroartemisinin-piperaquine (86.9

36 Patients received artesunate, administered orally at a daily dose of eithe

37 Sparse data on the safety of pyronaridine-artesunate after repeated treatment of malaria episodes

38 herefore compared the safety of pyronaridine-artesunate after treatment of the first episode of malar

39 tesunate (7 days) plus primaquine (14 days), artesunate alone or no treatment and followed up activel

40 with Hz formation, but their sensitivity to artesunate, also thought to be dependent on Hb degradati

41 cidence of gametocytemia was 33.6% following artesunate + amodiaquine (AS + AQ), 7.42% following arte

42 uch higher (36.0%; P < .05) than that of the artesunate-amodiaquine (2.9%) and artesunate-atovaquone-

43 14 days of PQ (0.25 mg base/kg) plus either artesunate-amodiaquine (AAQ + PQ) or dihydroartemisinin-

44 risk of recurrent parasitemia, compared with artesunate-amodiaquine (AS/AQ), but changing treatment p

45 was better tolerated than QnC (p=0.0005) and artesunate-amodiaquine (p<0.0001) in the modified intent

46 te and 8 early failures) were observed after artesunate-amodiaquine and atovaquone-proguanil therapie

47 with artemether-lumefantrine, but not after artesunate-amodiaquine or amodiaquine-sulfadoxine-pyrime

48 ised treatment of the fixed-dose combination artesunate-amodiaquine Winthrop((R)) (ASAQ) versus CQ fo

49 ous distribution of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaqui

50 ears old (n = 338) were randomly assigned to artesunate-amodiaquine, atovaquone-proguanil, or artesun

51 In large trials, parenteral artesunate (an artemisinin derivative) reduced severe ma

52 artesunate-mefloquine (target dose 12 mg/kg artesunate and 25 mg/kg mefloquine) or chloroquine (targ

53 administered initial intravenous therapy (38 artesunate and 49 quinine) followed by oral treatments.

54 emisynthetic artemisinin derivatives such as artesunate and artemether, along with the fully syntheti

55 rivatives of the clinical antimalarial drugs artesunate and artemether, in which a major metabolicall

56 ainst Plasmodium berghei ANKA, comparable to artesunate and artemether.

57 = .042) and 33% (P = .015) compared with the artesunate and control arms, respectively.

58 Values for artesunate and dihydroartemisinin were most affected.

59 Pharmacokinetic profiles of artesunate and dihydroartemisinin were similar between s

60 in rodents than the antimalarial drug sodium artesunate and is about 37 times more efficacious than s

61 pies for malaria, including mefloquine (MFQ)-artesunate and lumefantrine (LUM)-artemether.

62 nfections with C2A failed to clear upon oral artesunate and mefloquine treatment alone or in combinat

63 New drugs such as intravenous artesunate and oral artemisinin combinations, with incre

64 ted in a randomized comparison of parenteral artesunate and parenteral quinine in 9 African countries

65 those who could not were treated with rectal artesunate and referred to hospital.

66 NF54 = 7.3 nM) and comparable in potency to artesunate, and 35 exhibited 98% activity in the in vivo

67 % (95% CI, 13.1%-23.1%) for amodiaquine plus artesunate, and 6.7% (95% CI, 3.9%-11.2%) for artemether

68 rodents than either artelinic acid or sodium artesunate, and are strongly inhibitory but not cytotoxi

69 cytotoxic hematin, is potently inhibited by artesunate, and is associated with artesunate metabolism

70 ved pyrimethamine-sulfadoxine and 3 doses of artesunate, and it was 8-fold higher in the group that r

71 iation between an increased risk of MFQ, MFQ-artesunate, and LUM-artemether treatment failures and pf

72 rimethamine, 54 of 491 (11%) for amodiaquine+artesunate, and seven of 502 (1%) for artemether-lumefan

73 Here, we present a rapid screening assay for artesunate antimalarials based on reactive DESI.

74 Current artesunate (ARS) regimens for severe malaria are complex

75 Artesunate (ART) is an anti-malaria drug that has been s

76 support for the wider access to pyronaridine-artesunate as an alternative artemisinin-based combinati

77 e semi-synthetic artemisinins artemether and artesunate as they rapidly reduce parasite burden, have

78 Artesunate (AS) induces pitting, a splenic process where

79 Amodiaquine (AQ) is paired with artesunate (AS) or sulfadoxine-pyrimethamine (SP) in rec

80 Three days of treatment with artesunate (AS)-amodiaquine (AQ) combined with MB was co

81 thamine (SP), SP + amodiaquine (AQ), or SP + artesunate (AS).

82 We gave participants 4 mg/kg artesunate at 0, 24, and 48 h, 15 mg/kg mefloquine at 72

83 hat of the artesunate-amodiaquine (2.9%) and artesunate-atovaquone-proguanil (1.0%) groups.

84 sunate-amodiaquine, atovaquone-proguanil, or artesunate-atovaquone-proguanil treatment groups and fol

85 Artesunate-atovaquone-proguanil was a highly effective a

86 Artesunate-atovaquone-proguanil was not associated with

87 Moreover, artesunate attenuated the HS-induced activation of nucle

88 Moreover, artesunate attenuated the HS-induced activation of nucle

89 Artesunate attenuated the multiple organ injury and dysf

90 Artesunate attenuated the multiple organ injury and dysf

91 Artesunate attenuated the organ injury/dysfunction assoc

92 Artesunate attenuated the organ injury/dysfunction assoc

93 Particularly, artesunate-based antimalarial drugs have been targeted,

94 Furthermore, artesunate concentration-dependently blocked IgE-mediate

95 Children eligible for rectal artesunate contributed 1.1% of episodes.

96 Early treatment with chloroquine or artesunate did not prevent the anemia, suggesting that t

97 relationship between artemisinin treatments (artesunate, dihydroartemisinin, or artemether) and misca

98 and found that dihydroartemisinin (DHA) and artesunate displayed strong cytotoxic effects on HPV-imm

99 Splitting or increasing the artesunate dose did not shorten half-life in either site

100 P. falciparum infections from artesunate efficacy trials in Bangladesh, Cambodia, Laos

101 Pyronaridine-artesunate efficacy was compared with artemether-lumefan

102 Clinical trials of artesunate efficacy were conducted in Bangladesh, in nor

103 we confirmed that treatment of HS rats with artesunate enhanced the phosphorylation (activation) of

104 we confirmed that treatment of HS rats with artesunate enhanced the phosphorylation (activation) of

105 Artesunate exhibits pharmacological actions beyond its a

106 Artesunate exhibits pharmacological actions beyond its a

107 A 6-hour lag phase in artificial pitting of artesunate-exposed iRBCs was also observed in vitro.

108 In patients who had received artesunate for <10 hours, sequestration was higher in fa

109 protocols for early referral and intravenous artesunate for all severe malaria.

110 isinin-based combination therapy, and rectal artesunate for malaria treatment.

111 2), with a switch from quinine to injectable artesunate for management of severe disease and seasonal

112 ed for both Accelerate scenarios, and rectal artesunate for pre-referral treatment at the community l

113 n-based combination therapy (ACT) and rectal artesunate for severe malaria in children is proven.

114 mic African children treated with parenteral artesunate for severe malaria.

115 rtesunate was noninferior to mefloquine plus artesunate for the primary outcome: adequate clinical an

116 ation, providing a foundation for developing artesunate for the treatment of allergic asthma and othe

117 e+sulfadoxine-pyrimethamine, and amodiaquine+artesunate for treatment of uncomplicated malaria in Kam

118 ive pharmaceutical ingredients (for example, artesunate) for incorporation into ACTs.

119 e conventional 5-dose regimen of intravenous artesunate (given at 0, 12, 24, 48, and 72 hours) in Afr

120 artesunate group (50.6%) and the amodiaquine-artesunate group (48.5%) than in the dihydroartemisinin-

121 nificantly more frequently in the mefloquine-artesunate group (50.6%) and the amodiaquine-artesunate

122 p<0.0001) or sulfadoxine/pyrimethamine plus artesunate group (one of 198, 1%; p<0.0001).

123 lumefantrine group, 98.5% in the amodiaquine-artesunate group, 99.2% in the dihydroartemisinin-pipera

124 significant difference among the amodiaquine-artesunate group, dihydroartemisinin-piperaquine group,

125 isinin-piperaquine group, and the mefloquine-artesunate group.

126 peraquine group, and 96.8% in the mefloquine-artesunate group; the PCR-adjusted cure rates in the int

127 Two patients receiving mefloquine plus artesunate had seizures.

128 l role in endoperoxide-induced cytotoxicity (artesunate IC(50) values, 48 h: HeLa cells, 6 +/- 3 muM;

129 litting the dose of the short-half-life drug artesunate improves parasite clearance in falciparum mal

130 Intravenous artesunate improves survival in severe malaria, but clin

131 179 children treated with prereferral rectal artesunate in a multicountry study.

132 estigated potential anti-allergic effects of artesunate in animal models of IgE-dependent anaphylaxis

133 ifferences in treatment coverage with rectal artesunate in children aged <5 years in MUM vs CHW (stan

134 The total dose of artesunate in each group was 12 mg/kg.

135 reatment providers trained to provide rectal artesunate in Ghana, Guinea-Bissau, Tanzania, and Uganda

136 followed up after treatment with parenteral artesunate in Lambarene, Gabon, and Kumasi, Ghana.

137 i-allergic signaling mechanisms of action of artesunate in mast cells were also investigated.

138 g the effects of good manufacturing practice-artesunate in patients with trauma and severe hemorrhage

139 g the effects of good manufacturing practice-artesunate in patients with trauma and severe hemorrhage

140 men with a simplified regimen for parenteral artesunate in severe malaria.

141 rum malaria (<1%) who were treated with oral artesunate in Southeast Asia had a parasite clearance ha

142 ole hydrochloride as adjuvant to intravenous artesunate in the treatment of adults with severe falcip

143 Rectal artesunate interrupts disease progression by rapidly red

144 take oral drugs received prereferral rectal artesunate irrespective of RDT result and were referred

145 Artesunate is a clinically effective anti-malarial drug

146 Artesunate is a semi-synthetic derivative of artemisinin

147 Artesunate is a vital therapy for Plasmodium falciparum

148 Pyronaridine-artesunate is an artemisinin-based combination therapy u

149 Parasite clearance in response to artesunate is faster in Mali than in southeast Asia.

150 treat young children with prereferral rectal artesunate is feasible in remote communities of Africa,

151 Parenteral artesunate is recommended as first-line therapy for seve

152 rogen and the ether-like moieties within the artesunate lactone ring.

153 Deployment of mefloquine-artesunate (MAS3) on the Thailand-Myanmar border has led

154 ed with artemether-lumefantrine, amodiaquine-artesunate, mefloquine-artesunate, or dihydroartemisinin

155 The emergence of artesunate-mefloquine (AS+MQ)-resistant Plasmodium falci

156 A randomized, controlled trial of CQ vs artesunate-mefloquine (AS-MQ) for uncomplicated vivax ma

157 omly assigned 252 patients to receive either artesunate-mefloquine (n=127) or chloroquine (n=125); 22

158 isation (block sizes of 20), to receive oral artesunate-mefloquine (target dose 12 mg/kg artesunate a

159 within 28 days was lower in patients in the artesunate-mefloquine group (71 [62%; 95% CI 52.2-70.6])

160 Fever clearance was faster in the artesunate-mefloquine group (mean 11.5 h [95% CI 8.3-14.

161 with faster clearance of ring stages in the artesunate-mefloquine group (mean time to 50% clearance

162 as present in 44 (86%) of 51 patients in the artesunate-mefloquine group and 41 (84%) of 49 patients

163 One (<1%) patient in the artesunate-mefloquine group had a serious neuropsychiatr

164 pancy was 2426 days per 1000 patients in the artesunate-mefloquine group versus 2828 days per 1000 pa

165 (84% [95% CI 76-91]) of 115 patients in the artesunate-mefloquine group versus 61 (55% [45-64]) of 1

166 Artesunate-mefloquine is highly efficacious for treatmen

167 asite clearance was faster in patients given artesunate-mefloquine than in those given chloroquine (1

168 onotherapy and 5.4 (2.0-14.6, p=0.001) after artesunate-mefloquine therapy.

169 We aimed to compare artesunate-mefloquine with chloroquine to define the opt

170 therapies (ACTs, artemether-lumefantrine and artesunate-mefloquine) where the likelihood of increased

171 ibited by artesunate, and is associated with artesunate metabolism and susceptibility in drug-pressur

172 Rapid parasite killing by intravenous artesunate might obscure the effects of levamisole.

173 nes dissolved in the DESI spray solution and artesunate molecules exposed on the tablet surface.

174 artemisinin combination therapies (avoiding artesunate monotherapies) and single gametocytocidal low

175 oroquine, Sulfadoxine-Pyrimethamine and oral Artesunate monotherapy.

176 with a fixed-dose combination of mefloquine-artesunate (MQAS) or sulfadoxine-pyrimethamine plus amod

177 doxine-pyrimethamine (n=507), or amodiaquine+artesunate (n=515), or a 3-day six-dose regimen of artem

178 tment or re-treatment episodes, pyronaridine-artesunate (n=673) day 28 crude ACPR was 92.7% (95% CI 9

179 To evaluate the effects of artesunate on organ injury and dysfunction associated wi

180 ovided good evidence to support an effect of artesunate on the Akt-survival pathway, leading to downr

181 ovided good evidence to support an effect of artesunate on the Akt-survival pathway, leading to downr

182 ation of 180 mg of pyronaridine and 60 mg of artesunate or with 250 mg of mefloquine plus 100 mg of a

183 sulfadoxine-pyrimethamine, amodiaquine plus artesunate, or artemether-lumefantrine) when diagnosed w

184 fantrine, amodiaquine-artesunate, mefloquine-artesunate, or dihydroartemisinin-piperaquine.

185 In Cambodia, artesunate plus mefloquine may be a viable option to tre

186 aged 2-59 months received either one dose of artesunate plus one dose of sulfadoxine-pyrimethamine or

187 in-based combination therapy (ACT) or rectal artesunate plus referral when patients are unable to tak

188 We report here for the first time that artesunate possesses anti-allergic activity by blocking

189 Artesunate prevented IgE-mediated cutaneous vascular hyp

190 parum clinical episodes were observed in the artesunate-primaquine arm.

191 Treatment with artesunate-primaquine reduced the risk of P. vivax episo

192 nate-primaquine vs control, -58% [P = .004]; artesunate-primaquine vs artesunate, -49% [P = .031]) wi

193 ved only in the first 3 months of follow-up (artesunate-primaquine vs control, -58% [P = .004]; artes

194 hours from facilities for injections, rectal artesunate prior to hospital referral can prevent death

195 The clinically used trioxane drug sodium artesunate prolonged mouse average survival to 7.2 days

196 reatment of severe malaria, with intravenous artesunate proving superior to quinine.

197 No evidence was found that pyronaridine-artesunate re-treatment increased safety risk based on l

198 Artesunate reduced parasite clearance time and duration

199 Artesunate reduced posttreatment infectivity dramaticall

200 Artesunate remains the mainstay of treatment for cerebra

201 Artemisinin- and artesunate-resistant Plasmodium chabaudi mutants, AS-ART

202 The findings that pyronaridine-artesunate safety and efficacy were similar on first mal

203 esistance to mefloquine, and also to reduced artesunate sensitivity in vitro.

204 Patients with severe malaria treated with artesunate sometimes experience a delayed hemolytic epis

205 In addition, artesunate suppressed ovalbumin-mediated guinea pig bron

206 erapy for Plasmodium falciparum malaria, but artesunate tablets have been counterfeited on a very lar

207 ed to a set of recently collected suspicious artesunate tablets purchased in shops and pharmacies in

208 Fourteen different artesunate tablets, representative of what can be purcha

209 a until day 42 were higher with pyronaridine-artesunate than with mefloquine plus artesunate (10.2% [

210 icular concern was the positive detection of artesunate traces in the surface of one of the samples,

211 o reduce death from malaria by having rectal artesunate treatment available and used.

212 Increasing the artesunate treatment dose up to 8 mg/kg/d or splitting t

213 Prereferral artesunate treatment is a cost-effective, life-saving in

214 effectiveness of community-based prereferral artesunate treatment of children suspected to have sever

215 Prereferral rectal artesunate treatment was provided in 272 villages: 109 t

216 rs with parasite half-life assessments after artesunate treatment were analysed.

217 and parasite clearance half-lives following artesunate treatment.

218 art of a clinical trial comparing parenteral artesunate versus quinine (ISRCTN50258054).

219 about 37 times more efficacious than sodium artesunate via subcutaneous administration.

220 airwise comparisons, except amodiaquine plus artesunate vs artemether-lumefantrine, P = .05).

221 database was analyzed to compare outcomes of artesunate vs quinine treatment.

222 n day 42 in the group receiving pyronaridine-artesunate was 83.1% (705 of 848 patients; 95% CI, 80.4

223 that in the group receiving mefloquine plus artesunate was 83.9% (355 of 423 patients; 95% CI, 80.1

224 that in the group receiving mefloquine plus artesunate was 97.8% (360 of 368 patients; 95% CI, 95.8

225 efficacy in the group receiving pyronaridine-artesunate was 99.2% (743 of 749 patients; 95% confidenc

226 Artesunate was a safe and clinically beneficial alternat

227 Fixed-dose pyronaridine-artesunate was efficacious in the treatment of uncomplic

228 Direct mast cell-stabilizing effect of artesunate was examined in RBL-2H3 mast cell line and in

229 Artesunate was found to inhibit IgE-induced Syk and PLCg

230 Early referral and treatment with artesunate was highly effective for severe malaria from

231 Pyronaridine-artesunate was noninferior to mefloquine plus artesunate

232 severe and complicated malaria (artemether, artesunate) was prompt.

233 rsonnel (COMs); episodes eligible for rectal artesunate were established through regular household su

234 Anti-allergic actions of artesunate were evaluated in passive cutaneous anaphylax

235 ardized referral and prereferral intravenous artesunate were instituted at district hospitals.

236 acodynamic analysis suggests that 3 doses of artesunate were not inferior to 5 doses for the treatmen

237 amodiaquine and sulfadoxine-pyrimethamine or artesunate were significantly more efficacious, and each

238 id diagnostic tests (RDTs), ACTs, and rectal artesunate when provided by community health workers (CH

239 A combination of artesunate with mefloquine now cures more than 95% of ac